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Abstract. Mini-mu derivatives carrying plasmid replicons can be used to clone genes in 
vivo. This method was adopted to generate phasmid clones which were later screened for 
their ability of restore nitrofurantoin sensitivity of a nitrofuran-resistant host by eliciting 
nitroreductase activity. One phasmid-derived clone (pAJ101) resulted in considerable 
increase in nitroreductase activity when introduced into a nitrofurantoin-resistant mutant 
of Escherichia coli with reduced nitroreductase activity. Subsequently, a 1·8 kb fragment
obtained from pAJ101 by partial digestion with 5au3A, was subcloned into pUC18 to yield 
pAJ102. The nitroreductase activity attributable to pAJ102 was capable of reducing both 
nitrofurantoin and nitrofurazone. The polypeptides encoded by pAJ102 were identified by 
the minicell method. A large, well-defined band corresponding to 37 kDa and a smaller, 
less-defined band corresponding to 35 kDa were detected. Tnl000 mutagenesis was used to 
delineate the coding segment of the 1·8 kb insert of pAJ102. Α 0·8 kb stretch of DNA was 
shown to be part of the nitroreductase gene. The gene was mapped at 19 min on the 
Escherichia coli linkage map. 
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1. Introduction 
 
Nitrofurans are synthetic antimicrobial agents extensively used in human and 
veterinary medicine (reviewed by Grunberg and Titsworth 1973). The discovery of 
antibacterial activity in the 5-nitro derivatives of some 2-substituted furans (Dodd 
and Stillman 1944) led to the development of a series of such compounds with 
varying degrees of biological activity, many of which were put to clinical use. 
Although the subsequent discovery of side-effects such as pulmonary toxicity 
(Taskinen et al 1977; Holmberg and Bowman 1981), hepatic damage (Goodman 
and Gillman 1975; Black et al 1980), peripheral neuritis (Paul and Paul 1964) etc., 
led to a re-evaluation of their chemotherapeutic effectiveness vis-a-vis safety, a 
number of compounds have remained in use. Nitrofurazone (as a topical antiseptic), 
nitrofurantoin (in urinary tract infections) and furazolidone (for gastrointestinal 
infections in cattle and poultry) are some of the nitrofurans still in use.
Central to the biological activity of these drugs is their metabolic activation by a 
class of enzymes called nitroreductases (reviewed by Kedderis and Miwa 1988). 
These enzymes activate nitrofurans by mediating the reduction of their nitro group. 
The existence of nitroreductases and the constitutivity of expression of the 
corresponding genes in many bacteria are obviously responsible for the broad 
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spectrum of antibacterial activity of these drugs. However, the normal physiological 
role of these enzymes is not known. Despite the large body of evidence relating 
nitroreductase activity with nitrofuran sensitivity of bacteria, the individual steps in 
the mode of activation have not been studied in detail. Development of resistance to 
a nitrofuran is usually attributed to mutations which result in the loss of 
nitroreductase activity (Asnis 1957; McCalla et al 1970, 1975, 1978; Bryant et al 
1981). In Escherichia coli, oxygen-sensitive (type II) and oxygen-insensitive (type I) 
nitroreductase activities have been identified (Asnis 1957; McCalla et al 1970, 1975, 
1978). The oxygen-insensitive activity consists of major and minor components 
(McCalla et al 1978), the genes for which have been designated nfsA and nfsB, 
respectively. The minor nitroreductase activity has been shown to consist of two 
independent entities (Bryant et al 1981). The genes coding for the oxygen-insensitive 
nitroreductases have been broadly mapped to the lac-gal region (McCalla et al 
1978). The precise map positions were however not identified. Two-step 
nitrofurazone-resistant mutants (see below) were shown to have lost the major 
nitroreductase activity and one of the two minor activities (McCalla et al 1978). 
Taking advantage of the correlation between nitrofurantoin resistance and loss of 
nitroreductase activity, we used a nitrofurantoin-resistant mutant as a host to 
isolate potential nitroreductase clones by screening for restoration of nitroreductase 
activity and drug sensitivity. In the present communication we report the cloning of 
a 1·8 kb fragment carrying the nitroreductase gene, identification of the encoded 
polypeptide and mapping of the cloned nitroreductase gene.
 
 
2. Materials and methods 
 
2.1 Bacterial strains and plasmids 
 
The E. coli strains and the plasmids used are listed in table 1.
 
2.2 Chemicals 
 
All chemicals were obtained commercially and were of analytical grade. 35S 
methionine was obtained from Amersham, England through Bhabha Atomic 
Research Centre, Bombay. ATP and NADPH were from Boehringer-Mannheim, 
Germany. Enzymes and other chemicals used during DNA manipulations were 
obtained from New England Biolabs, USA, Amersham, England and BRL, USA. 
The concentrations (µg/ml) of the antibiotics used were as follows: ampicillin, 100; 
tetracycline, 20; kanamycin, 40 and chloramphenicol, 6. Nitrofurantoin (Sigma 
Chemical Co., USA) was used at varying concentrations depending on the 
experiment. 
 
2.3 Isolation of nitrofurantoin resistant mutants 
 
Spontaneous nitrofurantoin-resistant mutants were isolated by plating approxima- 
tely 107 cells of AB 1157 on L-plates containing 10 µg/ml of the drug and incubating 
the plates at 37°C. Putative mutants were patched on to fresh L-plates containing 
the same concentration of nitrofurantoin. The stability of the mutation was assessed 
by growing these mutants for several cycles in non-selective L-medium and plating 
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Table 1. Bacterial strains and plasmids.
 
 
suitable dilutions on L-nitrofurantoin and L-streptomycin plates. Α mutant (AJ101) 
which fulfilled the criterion of matching titres on both types of plates was 
lysogenized with Mu cts62 to give AJ102. A two-step mutant AJ212 was obtained 
from AJ102 as before but by spreading the cells on L-plates containing 70 μg/ml 
nitrofurantoin.
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2.4     Generation of phasmid library and screening for nitroreductase clones
 
AB 1157 was lysogenized with Mu cts62 phage to give AJ251 which in turn was 
transformed to kanamycin resistance with pEG5005 isolated from Xph43Mu cts 
harbouring the phasmid. The lysate, obtained from pEG5005/AJ251 by heat 
induction, was used to transduce AJ212 to kanamycin resistance according to the 
protocol of Groisman and Casadaban (1986). The kanamycin-resistant trans- 
ductants were screened for loss of ampicillin resistance to select for phasmids with 
an included chromosomal fragment (Groisman et al 1984). The kanamycin- 
resistant, ampicillin-sensitive transductants were gridded on to L-nitrofurantoin (70 
and 30 µg/ml) and L-kanamycin plates. Since interpretation of nitrofurantoin 
resistance/sensitivity is often obscured by cell density, care was taken to make thin 
and broad patches while gridding. The transductants which showed no (or least) 
growth on L-nitrofurantoin plates were later assayed for nitroreductase activity.
 
2.5 Nitroreductase assays 
 
2.5a Reduction of nitrofurantoin by whole cells: Strains were grown overnight in 
L-medium, diluted 1:100 in fresh medium and aerated at 30°C till mid-log phase. 
Appropriate antibiotics were included in the growth medium in the case of plasmid- 
bearing strains. The cells were collected, washed with M/15 phosphate buffer (pH 
7·2) and the-absorbance at 600 nm was adjusted to 0·4. Glucose was added to 0·2% 
and the suspension was aerated at 30° C for 30 min. Nitrofurantoin was added to a 
concentration of 20 µg/ml and aeration continued. Three ml aliquots were removed 
at intervals, centrifuged in a microfuge for 3 min and the absorbance of the 
supernatant was measured at 372 nm (the absorption maximum of nitrofurantoin). 
Rate of nitrofurantoin reduction by whole cell suspensions was expressed as nmol 
reduced/ml. A decrease of 0·06 units in absorbance was taken to correspond to the 
reduction of 10 nmol of nitrofurantoin. Each value was obtained as an average of 
three independent experiments.
 
2.5b Reduction of nitrofurantoin and nitrofurazone by cell free extracts: The cells
were grown as above, collected, washed with M/15 phosphate buffer (pH 7·2) and 
resuspended in the same buffer at 1/20 the original volume. The cells were lysed by 
sonication in a Labline ultrasonic system, with several 30s pulses at 100 W with 1- 
min intervals, the cells being kept cold on ice. The lysate was clarified at 100,000 g for 
1 h at 4°C and the organelle-free supernatant was assayed for nitroreductase 
activity. The assay mixture contained: 300 μg NADPH, enzyme extract, nitro- 
furantoin (0·25 µmol) or nitrofurazone (0·3 µmol) and M/15 phosphate buffer (pH 
7·2) in a total volume of 3 ml. The assay mixture was preincubated at 25° C without 
NADPH for 10 min and the reaction was initiated by the addition of NADPH. The 
reduction was monitored at 372 nm (nitrofurantoin) or 375 nm (nitrofurazone). The 
amount of drug reduced was calculated as follows: reduction of 10 nmol of 
nitrofurantoin and nitrofurazone results in a decrease of 0·06 and 0·05, respectively, 
at the respective absorption maximum. Each value was obtained as the average of 
three independent experiments. Protein was estimated by the method of Lowry et al 
(1951). Reductase activity was expressed as nmol of nitrofuran reduced/min/mg 
protein. 
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2.6 DNA manipulations 
 
DNA manipulations were carried out according to the protocols outlined by 
Silhavy et al (1984). Subcloning of the nitroreductase gene was accomplished by 
digesting pAJ101 (see 'results') with different concentrations of Sau3A and ligating 
the digest containing the maximum number of fragments in the 1·8–2·4 kb range, 
into the BamHI site of pUC18. The ligated mixture was used to transform AJ212 to 
ampicillin resistance. 
Cartridge mutagenesis with the 1·9 kb BamHI fragment from pKU602, carrying 
the kanamycin resistance gene, was performed by ligating the BamHI fragment into 
the Bg1II site within the nitroreductase gene (see 'results').
 
2.7 Genetic techniques 
 
P1 transductions and conjugational crosses were carried out according to Miller 
(1972) and Silhavy et al (1984), respectively. Integrative recombination of pAJ102 
and pAJ103 was achieved essentially by the protocol of Cunningham and Weiss 
(1985). However, immediately after transformation the plates were incubated at 
30° C. The transformants were pooled and grown in L-medium for a few 
generations at 30° C before the culture was subjected to alternating temperature 
shifts from 30° to 42° C and vice versa.
 
2.8 Mutagenesis with Tn1000 
 
RJ101 carrying F'128 was transformed to ampicillin resistance with pAJ102. One of 
the transformants was used as donor in a cross with AJ212 (as recipient) and 
ampicillin-resistant transconjugants were obtained. The ampicillin-resistant trans- 
conjugants were screened for nitrofurantoin sensitivity/resistance by gridding on L- 
nitrofurantoin plates (30 µg/ml) and were also subjected to restriction analysis (see 
'results'). 
 
2.9 Identification of plasmid-encoded polypeptides 
 
Plasmid-encoded polypeptides were identified by the minicell method of Komai et 
al (1982). The minicell-producing strain DS410 was transformed to ampicillin 
resistance with pUC18 (control) and pAJ102 separately. Minicells were isolated on 
discontinuous sucrose gradients and labelled with 35S methionine. The labeled 
minicells were mixed with sample buffer, kept in a boiling water bath for 3 min and 
the proteins were electrophoresed according to Laemmli (1970). The gel was 
fluorographed with PPO as the scintillant according to the method of Bonner and 
Laskey (1974), dried under vaccum and exposed to Indu X-ray film at – 70°C.
 
2.10 Monitoring the response of AJ212 and AJ212/pAJ102 to nitrofurantoin
challenge 
 
Overnight cultures of AJ212 in L-medium, and AJ212 harbouring pAJ102, in L-
medium containing ampicillin, were diluted 1:100 in fresh L-medium and grown to
a density of approximately 5 × 107 cells/ml. Nitrofurantoin was added to both
cultures at 20 µg/ml and aeration continued. The kinetics of killing was monitored
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by removing aliquots at 30-min intervals and plating suitable dilutions on L-plates. 
The plates were incubated at 30° C for 24 h to score for the survivors.
 
3. Results 
 
3.1 Isolation of nitrofurantoin-resistant mutants 
 
A stable mutant (AJ101) which satisfied the criterion of matching titres on media 
with and without nitrofurantoin was isolated as described under experimental 
procedures. It was found to tolerate up to 40 μg/ml nitrofurantoin although it was 
isolated on an L-plate containing 10 µg/ml nitrofurantoin. AJ101 was lysogenized 
with Mu cts62 to give AJ102. Whole cell suspensions of AJ102 displayed very low 
levels of nitroreductase activity (figure 1). Subsequently, a two-step mutant, AJ212, 
was isolated from AJ102. However, in the case of the two-step mutant, the high 
level of resistance was not stably maintained. Immediately after isolation the strain 
tolerated the drug up to a concentration of 100 µg/ml but on prolonged storage 
followed by growth in drug-free media the level of resistance dropped considerably. 
In any case, the level of resistance was greater than that of the parent strain, AJ101. 
The nitroreductase levels of the one- and two-step mutants were however the same 
(figure 1). In the light of these observations the nature of the second level 
nitrofurantoin resistance mutation in AJ212 is uncertain.
 
3.2 Cloning of the nitroreductase gene 
 
The cloning strategy involved the generation of a phasmid-based library of a 
 
Figure 1. Nitroreductase activities of whole-cell suspensions.
(•), AJ212 carrying pAJ102;(⁪)AJ212 carrying pAJl0l; (O), AJ102;(Δ)AJ212.
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nitrofuran-sensitive strain, transforming a nitroreductase deficient, nitrofurantoin- 
resistant strain and selecting a clone in which nitroreductase levels and drug 
sensitivity are restored. The phasmid-based clones obtained as described under 
experimental procedures were used to transduce AJ212 to kanamycin resistance. 
Approximately 5000 kanamycin-resistant transductants were screened initially for 
sensitivity to ampicillin and the ampicillin-sensitive clones were screened for 
nitrofurantoin sensitivity. Ten potential nitroreductase clones were isolated based 
on the extent of their growth on L-plates containing 70 and 30 µg/ml of 
nitrofurantoin and the levels of nitroreductase activity in whole-cell suspensions. 
However, only one of the isolates displayed stable nitrofurantoin sensitivity. The 
presence of the phasmid (pAJl0l) in this clone resulted in a substantial increase in 
nitroreductase activity in whole cell suspensions (figure 1). There was a 
corresponding increase in the activity in cell-free,extracts (table 2).
 
3.3 Subcloning and restriction analysis of the nitroreductase gene
The nitroreductase gene was subcloned into pUC18. In an earlier report by 
McCalla et al (1978) the sizes of the major and minor nitroreductases were 
estimated to be 56 and 38 kDa respectively. Therefore random fragments in the 1·8– 
2·4 kb size range, obtained by partial digestion of pAJl0l DNA with Sau3A, were 
ligated with BamHI linearized pUC18 and used to transform AJ212 to ampicillin 
resistance. The transformants were screened for nitrofurantoin sensitivity and 
assayed for nitroreductase activity. One of the transformants displayed enhanced 
nitroreductase activity and carried a recombinant plasmid (pAJ102) with a 1·8 kb 
insert. Assays of the nitroreductase activities attributable to pAJl0l, pAJ102 and 
the mutant host AJ212, both in vivo (figure 1) and in vitro (table 2) clearly 
demonstrate that pAJ102 includes the nitroreductase gene. The higher level of 
reductase activity due to pAJ102 can be attributed to the copy number of the 
plasmid. The possession of pAJ102, renders the cell hypersensitive to nitrofurantoin 
(see below). Since nitroreductases are known to activate a variety of nitrofurans, the 
activity was assayed with both nitrofurantoin and nitrofurazone as substrates (table 
2). It is apparent that the activity is not restricted to nitrofurantoin but extends to 
atleast one other nitrofuran.
The presence of convenient restriction sites on the vector facilitated restriction 
analysis of the 1·8 kb insert. A partial restriction map of the 1·8 kb insert is depicted 
in figure 2a. 
 
3.4 Mutagenesis of pAJ102 with Tn1000 (γδ)
 
In order to delineate the segment coding for nitrofuran reductase within the 1·8 kb 
 
 
Table 2. Nitrofuran reductase activities in vitro.
 
 
anmol of drug reduced/min/mg protein.
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Figure 2.   (A)  Partial restriction map of insert in pAJ102.
(B)Location of Tnl000 on the 1·8 kb insert of pAJ102.
Tnl000 in γδ (∇,▼) and δγ (Δ,▲) rientation not affecting (∇,Δ) and inactivating 
(▼,▲) nitroreductase. 
(C)Partial restriction map of the chromosomal insert in pAJl0l. The arrow indicates 19th
min of the E. coli genetic map.
The left and right ends of the figure correspond to the HindIII and Eco RI ends of the 
multiple cloning site of pUCl8. Scale (A) and (B), 1 cm = 0·l kb. (C) 1 cm= 1·0 kb. 
 
 
insert of pAJ102, Tnl000 mutagenesis was carried out. The plasmid was first 
introduced into an F'-bearing strain (RJ101) and subsequently mobilized into a 
nitrofurantoin-resistant recipient (AJ212) selecting for ampr transconjugants. F- 
mediated mobilization of non-conjugal plasmids involves transposition of the γδ 
(Tnl000) element on to the plasmid, cointegrate formation, transfer through the F- 
conjugal system and resolution of the cointegrate in the recipient. Transposition of 
Tnl000 could result in insertional Inactivation of gene function. Since pAJ102 
harbours an insert coding for nitroreductase, insertions into the coding segments 
could be picked up by screening for loss of enzyme activity. The recipient (AJ212) is 
deficient in nitroreductase and is resistant to nitrofurantoin (see above). 
Introduction of a plasmid containing an insertionally-inactivated nitroreductase 
gene would not affect the resistance status of the host while introduction of a 
functional gene would. Screening for the persistence of nitrofuran resistance of the 
recipient would allow the detection of clones inheriting the insertionally- inactivated 
gene. However, loss of resistance would not distinguish between insertions on the 
vector and those in regions of the insert not coding for nitroreductase. Therefore 
the ampr transconjugants were also subjected to restriction analysis which revealed 
sixteen insertions within the 1·8 kb insert of pAJ102. Using the known restriction 
maps of pUC18 and Tnl000 the orientations of Tnl000 in each of the insertions 
were also determined. Figure 2b presents the data. It can be seen from figure 2b 
that Tnl000 insertions in 0·5 kb of DNA at the left end of the 1·8 kb insert do not 
inactivate the nitroreductase gene (insertion nos 4, 6, 9 and 16). Insertions in the 
next 0·8 kb of DNA (nos 5, 11, 13, 71, 73, 76, 79, 81, 82, 83, 84 and 85) inactivated 
the gene. For reasons not known we did not get insertions in the last 0·5 kb of the 
insert. Therefore the maximum stretch of DNA available in the 1·8 kb insert for 
encoding the nitroreductase enzyme is 1·3 kb. Accordingly the size of the encoded 
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polypeptide could be approximately 40 kDa. Superimposition of the partial 
restriction map of the 1·8 kb insert and the map of the Tn1000 insertions into the 
same clearly shows the inclusion of the PvuII and BgIII sites within the coding 
region. 
 
3.5 Identification of plasmid-encoded polypeptides 
 
The minicell producing strain DS410 was transformed to ampicillin resistance with 
pUC18 (control) and pAJ102. The minicells were isolated on discontinuous sucrose 
gradients, labelled with 35S methionine and the proteins were solubilized with 
sample buffer. The plasmid-encoded polypeptides were identified by SDS-PAGE 
followed by autoradiography (figure 3). Two additional polypeptides were observed 
in minicells harbouring pAJ102 (figure 3, lane 2): a major band corresponding to 
37 kDa and a minor band corresponding to 35 kDa. The major band was well- 
defined whereas the minor band was somewhat fuzzy and ill-defined. Considering 
the stretch of DNA in the 1·8 kb insert identified to constitute the nitroreductase 
gene (described above), the 37 kDa polypeptide should be the nitroreductase protein 
while the 35 kDa polypeptide can be attributed to degradation or processing of the 
37 kDa polypeptide.
 
3.6 Kinetics of survival of AJ212 and AJ212 harbouring pAJ102 upon nitrofurantoin 
challenge 
 
Since there is a direct correlation between nitrofuran reductase activity and 
nitrofuran sensitivity, an enhancement in nitroreductase activity would lead to 
increased nitrofuran sensitivity. The effect of nitrofurantoin on the viability of 
AJ212 (control) and AJ212 harbouring pAJ102 was monitored at different time 
intervals after exposure to nitrofurantoin. At a concentration of 20 µg/ml, 
nitrofurantoin drastically affected the survival of AJ212 harbouring the nitrore- 
ductase clone (figure 4). Within 30 min of addition of the drug, the number of 
survivors decreased more than 100-fold. (At earlier intervals, there was inhibition of 
colony-forming ability. On prolonged incubation in the absence of the drug, cells 
did grow to form colonies). In the case of normal, plasmid-free, nitrofuran-sensitive 
cells it takes approximately 7 h to obtain the same level of killing under identical 
conditions (D Ν Simha and R Jayaraman, unpublished results). The presence of 
pAJ102 did not affect the growth of AJ212 in the absence of nitrofurantoin (data 
not shown). 
 
3.7 Mapping of the nitroreductase gene 
 
A previous report (McCalla et al 1978) had indicated only the approximate map 
locations of the nitroreductase genes. In order to map the location of the gene that 
we had cloned, two approaches were followed. In one, the plasmid carrying the 
cloned gene was forced to integrate into the chromosome. This resulted in the 
transfer of plasmid-borne drug resistance marker to a chromosomal locus, 
homologous to the insert carried on the plasmid. The drug resistance marker was 
then utilized to map the locus of integration by conventional methods. Since DNA 
polymerase I is essential for the replication and maintenance of colEI replicons, 
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Figure 3. Detection of plasmid-encoded polypeptides by the minicell method. DS410 was 
transformed separately with pUC18 (control) and pAJ102. The minicells were isolated on 
discontinuous sucrose gradients and labelled with 35S methionine. The plasmid-encoded 
polypeptides were identified by PAGE followed by autoradiography.
Lane 1: pUC18 encoded polypeptides. Lane 2: pAJ102 encoded polypeptides. Arrow 
indicates position corresponding to 37 kDa.
 
 
selection for drug resistance under conditions which rendered the enzyme inactive 
would yield derivatives with the plasmid integrated into the chromosome. Towards 
this end a polA ts strain (MM383) was transformed with pAJ102 and the ampicillin- 
resistant transformants were subjected to alternate cycles of growth at 30° and 
42° C. In another experiment a drug resistance marker was first introduced into the 
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Figure 4.  Response of AJ212 and AJ212 harbouring pAJ102, to nitrofurantoin challenge.
(O), AJ212; (•), AJ212 harbouring pAJ102.
 
 
nitroreductase gene as follows. Since the BglII site lies within the gene (see above) a 
1·9 kb BamHI fragment from pKU602 carrying the gene for kanamycin resistance 
was ligated into it (cartridge mutagenesis). The resultant plasmid pAJ103 was used 
to transform MM383. Chromosomal integration of pAJ103 was achieved as 
described above for pAJ102. 
The kanamycin and ampicillin resistance markers (due to integrated pAJ103 and 
pAJ102) from two derivatives of MM383 (AJ321 and AJ301), were transduced into 
AB3027. The nitroreductase activities of whole-cell suspensions of a kanamycin 
resistant transductant (AJ322) and an ampicillin-resistant transductant (AJ302) were 
determined as before. It is apparent from figure 5 that integration of pAJ102 led to 
a slight increase in nitroreductase activity whereas integration of pAJ103 did not. 
This can be explained by the fact that integration of pAJ102 which has an intact 
nitroreductase gene would give rise to two functional copies of the gene whereas 
integration of pAJ103 would still have only one functional copy of the gene. The 
duplication of the nitroreductase gene as a result of integration of pAJ102 leads to 
an increase in nitroreductase activity (figure 5).
Conjugational crosses between AJ322 (as the recipient) and various Hfrs showed 
that a good proportion of gal+ recombinants lost kanamycin resistance (table 3) 
suggesting that the cloned gene could lie in the vicinity of the gal locus. 
Subsequently, the kanamycin resistance marker of pAJ103 and the ampicillin 
resistance marker of pAJ102 were mapped by transduction of tetracycline resistance 
from strains carrying Tnl0 insertions close to the gal locus and screening the tetr
transductants for the loss of kanamycin and ampicillin resistance, respectively. 
Reciprocally, the kanamycin resistance marker of AJ322 was transduced into 
RW1230 and the kanr transductants were screened for loss of tetracycline resistance. 
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Figure 5. Nitroreductase activities of whole-cell suspensions of AJ302(O), ΑΒ3027(Δ) 
and AJ322(□). 
 
 
Table 3.  Conjugational crosses between AJ322 and various Hfrs.
 
c: Clockwise; cc: counter clockwise.
 
 
Table 4. Transductional mapping of the nitroreductase gene.
 
The results of the transductional analyses are presented in table 4. It can be seen 
that the nitroreductase locus is cotransducible with the Tnl0 insertions in RW1230 
and S1316 at a low frequency (1–4%). This observation suggests that the gene could 
lie between the loci of the two Tnl0 insertions (17–19 min). Calculation of the map 
distances using Wu's formula (Wu 1966; taking L = 2·3) would place the position of 
the nitroreductase gene between 18·5 and 19·1 min on the linkage map. Table 4 also 
shows that the nitroreductase locus is very highly cotransducible with cmlA
(18·8 min). Thus the transductional analyses suggest that the nitroreductase gene 
could be located at 18·8 min.
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In the second approach the restriction profile of the chromosomal insert in 
pAJ101 (figure 2C) and the restriction map of the E. coli genome (Kohara et al 
1987) in the region indicated by genetic methods were compared. The restriction 
map of the E. coli chromosome at a location close to 19 min (18·8–19·1 min;
kilobase coordinates approximately 895 to 915) matches precisely with the 
restriction map of the insert in pAJ101. The gene can therefore be placed at 19 min. 
The PvuII site within the nitroreductase gene facilitated the identification of the 
map position. The slight discrepancy between the map positions obtained by the 
two methods can be ascribed to the relative imprecision of conventional genetic 
methodologies. 
 
 
4. Discussion 
 
In this report we have presented data on the cloning and characterization of a gene 
from E. coli coding for nitrofuran reductase. Since nitrofuran resistance and 
nitroreductase activity bear an inverse correlation we isolated a nitrofurantoin- 
resistant mutant with low levels of nitroreductase activity and used this to screen 
phasmid-based clones for restoration of enzyme activity and drug sensitivity. A 
1·8 kb fragment of the chromosomal insert of one such clone obtained this way 
(pAJ101) was subcloned into pUC18, to give pAJ102. The observation that the 
nitroreductase activity of the host strain was very low in whole cell suspensions as 
well as cell-free extracts showed that the mutation inactivated the nitroreductase 
gene rather than creating a simple permeability barrier to nitrofurantoin. The 
restoration of nitroreductase activity by pAJ101 and pAJ102 in whole cells as well 
as cell-free extracts showed that the plasmids contain the gene coding for the 
enzyme. Possession of pAJ101 and pAJ102 renders AJ212, a nitrofurantoin- 
resistant mutant, highly sensitive to the drug. Although an earlier report (Herrlich 
and Schweiger 1976) suggested that unreduced nitrofurantoin can also have 
biological activity, our results demonstrate the need for reductive activation.
The identity of the cloned gene with nfsA or nfsB genes defined by McCalla et al 
(1978) can be deduced from the size of the encoded polypeptide, map position of the 
gene and level of enzyme activity due to a single copy of the gene. From the size of 
the coding segment of the insert (≤1·3 kb, as determined by Tn1000 mutagenesis)
and the size of the polypeptide (37 kDa) identified in minicells, it is probable that 
the cloned gene could be nfsB. However the map location of the gene is at variance 
with that reported by McCalla et al (1978). Although the authors had not reported 
precise map positions, they had suggested that the order of loci in the relevant 
region could be lac (8 min) nfsB (?) galK (17 min) nfsA (?). That is, nfsB lies before 
17 min on the E. coli linkage map. Our mapping data presented herein place the 
cloned gene at 19 min. However, a careful and critical analysis of the genetic data 
reported by McCalla et al (1978) does show that the more probable order could be 
lac gal nfsB nfsA. If this were so, nfsB would fall in the same position as reported 
herein. McCalla et al (1978) had isolated a two-step nitrofurazone-resistant mutant 
(NFR 502) which lacked both the major and minor nitroreductases. When this 
strain was transduced to kanamycin resistance using P1 propagated on AJ322 (see 
'results') the nitroreductase activity was restored to only 10% of wild type levels 
(unpublished results). It could be recalled that AJ322 contains two copies of the 
nitroreductase gene, only one of which is functional and the other inactivated by
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insertion of the kanamycin-resistant determinant. Transduction of kanamycin 
resistance using AJ322 as donor, in effect, introduces a single functional copy of the 
nitroreductase gene. The observation that enzyme activity is restored only to 10% 
of normal levels suggests that the cloned gene codes for the minor nitroreductase. 
The major and minor nitroreductases have been reported to differ in their 
sensitivity to 2 Μ urea. While McCalla et al (1978) showed that the minor enzyme 
was sensitive, Breeze and Obeseiki-Ebor (1983) have shown exactly the opposite. 
We have partially purified the enzyme encoded by the insert carried on pAJ102, by 
affinity chromatography on Sepharose CL-6B and found the partially purified 
enzyme to be relatively insensitive to urea (25% loss of activity after 45 min 
exposure to 2 Μ urea at 37°C; unpublished results). In view of the existence of 
mutually contradictory reports, urea sensitivity is not a satisfactory criterion to 
establish the identity of nitrofuran reductases. However, based on other criteria 
reported herein we believe that the gene we have cloned is nfsB. Thus, this work has 
established the precise map position of one of the genes involved in nitrofuran 
toxicity. Watanabe et al (1989, 1990) have reported the cloning of a nitroreductase 
gene of Salmonella typhimurium. The size of the corresponding polypeptide was 
found to be 28 kDa. Since several enzymes are known to be involved in the 
metabolism of nitroheterocycles, it is difficult to say whether the gene cloned by 
Watanabe et al (1989, 1990) is analogous to the one reported herein.
pAJ102 can be exploited as a cloning vector since insertion of extraneous DNA 
into the nitroreductase gene will inactivate it and thereby permit direct selection 
when transformed into a nitrofurantoin-resistant host. This is currently being 
assessed. 
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